Work

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

Year: 2009

Type: article

Study design: Clinical Trial

Source: Cancer Gene Therapy

DOI: 10.1038/cgt.2009.15

Authors: J Nemunaitis, M Nemunaitis, N Senzer, P Snitz, C Bedell, P Kumar, B Pappen, P B Maples, D Shawler, H Fakhrai

Institutions: Mary Crowley Cancer Research Center, Baylor University Medical Center, Gradalis (United States), NovaRx (United States)

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1993615391

FWCI: 5.099

Cites: 35

Cited by: 154

Related to: 10